IN8bio (INAB) is trading up at $1.42 (+1.43%), as of the latest quote. It operates in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$8.56M | −$14.7M | −$28.5M | −$30.0M | −$30.4M | −$19.4M |
| Net income | −$8.56M | −$14.7M | −$28.5M | −$30.0M | −$30.4M | −$19.4M |
| EPS (diluted) | −$2718.00 | −$44.10 | −$40.80 | −$30.00 | −$17.05 | −$4.44 |
| Balance sheet | ||||||
| Cash and equivalents | $18.1M | $37.3M | $18.4M | $21.5M | $11.4M | $27.3M |
| Total assets | $20.9M | $42.2M | $33.0M | $33.7M | $20.9M | $32.3M |
| Total liabilities | $2.59M | $4.04M | $10.3M | $8.77M | $6.47M | $4.72M |
| Shareholders' equity | −$16.6M | −$38.2M | $22.7M | $24.9M | $14.5M | $27.6M |
| Cash flow | ||||||
| Operating cash flow | −$7.13M | −$13.5M | −$24.1M | −$23.3M | −$24.1M | −$12.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$7.09M | −$6.16M | −$5.55M | −$5.09M | −$3.85M | −$4.94M | −$5.09M | −$4.78M |
| Net income | −$7.09M | −$6.16M | −$5.55M | −$5.09M | −$3.85M | −$4.94M | −$5.09M | −$4.78M |
| EPS (diluted) | −$4.49 | −$1.05 | −$2.16 | −$1.24 | −$0.85 | −$0.19 | −$0.26 | −$0.25 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.26M | $11.4M | $12.2M | $13.5M | $11.0M | $27.3M | $22.2M | $18.1M |
| Total assets | $16.0M | $20.9M | $19.9M | $19.4M | $16.8M | $32.3M | $26.3M | $21.7M |
| Total liabilities | $7.38M | $6.47M | $5.99M | $4.13M | $3.58M | $4.72M | $3.48M | $3.38M |
| Shareholders' equity | $8.59M | $14.5M | $13.9M | $15.2M | $13.2M | $27.6M | $22.8M | $18.4M |
| Cash flow | ||||||||
| Operating cash flow | −$6.11M | −$4.03M | −$3.12M | −$3.93M | −$3.52M | −$2.14M | −$4.95M | −$3.75M |
| Capital expenditure | $0 | — | $0 | $0 | $0 | — | — | — |
| Free cash flow | −$6.11M | — | −$3.12M | −$3.93M | −$3.52M | — | — | — |
From IN8bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning IN8bio in our feed yet.